OPK Stock Climbs 32.5% YTD: What's Driving the Rally in 2026?
OPKO Health is gaining on pharmaceutical growth, a broad clinical pipeline, strategic partnerships and fresh non-dilutive financing.
Zacks Investment Research9/21/2026Positive
OPK
Opko Health IncNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$1.22B
P/E Ratio
—
EPS
$-0.07
Beta
1.50
52W High
$1.75
52W Low
$0.98
50-Day MA
$1.45
200-Day MA
$1.31
Dividend Yield
—
Profit Margin
-12.40%
Forward P/E
53.76
PEG Ratio
93.65
About Opko Health Inc
OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.
Fundamentals
| Revenue (TTM) | $587.90M |
| Gross Profit (TTM) | $114.48M |
| EBITDA | $-78.17M |
| Operating Margin | -15.30% |
| Return on Equity | -5.88% |
| Return on Assets | -5.52% |
| Revenue/Share (TTM) | $0.75 |
| Book Value | $1.59 |
| Price-to-Book | 1.07 |
| Price-to-Sales (TTM) | 2.08 |
| EV/Revenue | 2.324 |
| EV/EBITDA | 24.89 |
| Quarterly Earnings Growth (YoY) | -12.60% |
| Quarterly Revenue Growth (YoY) | 4.30% |
| Shares Outstanding | $746.33M |
| Float | $323.73M |
| % Insiders | 50.52% |
| % Institutions | 27.56% |
Historical Volatility
HV 10-Day
32.50%
HV 20-Day
57.17%
HV 30-Day
51.16%
HV 60-Day
84.83%
HV Rank
86.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($4.38 target)
2
Strong Buy2
Buy2
HoldLatest News
OPKO Health Pivots to Therapeutics, Eyes Data-Rich 12 to 18 Months
OPKO Health NASDAQ: OPK outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
MarketBeat9/11/2026Neutral
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that Elias A.
GlobeNewsWire9/8/2026Neutral
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research8/26/2026Negative
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
Zacks Investment Research8/24/2026Positive
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
Zacks Investment Research8/19/2026Neutral
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.
Zacks Investment Research8/19/2026Positive
OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.
Zacks Investment Research8/19/2026Positive
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.
Zacks Investment Research8/18/2026Positive
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside
GlobeNewsWire8/13/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OPK and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 9/28/2026